Ascendis Pharma's Once-Weekly Growth Hormone Matches Daily Therapy in Turner Syndrome Trial
ASND sits 86% above its 52-week low of $124.06.
Summary
Ascendis Pharma announced positive Week 52 topline results from its Phase 2 New InsiGHTS trial for TransCon hGH (lonapegsomatropin) in prepubertal children with Turner syndrome. The once-weekly treatment demonstrated comparable efficacy and safety to daily somatropin, with an annualized height velocity of 9.05 cm/year, similar to the 9.04 cm/year for the daily treatment. This is a significant positive development as TransCon hGH is already FDA-approved for other growth hormone deficiencies, and these results support its potential for label expansion into Turner syndrome, a new indication. The company plans further study in its Phase 3 HighLiGHts basket trial, which will be a key catalyst to watch for this pipeline asset.
At the time of this announcement, ASND was trading at $231.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.2B. The 52-week trading range was $124.06 to $248.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.